Live feed07:00:00·556dPRReleasevia QuantisnowGroundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder CancerByQuantisnow·Wall Street's wire, on your screen.CGON· CG Oncology Inc.Health Care
